Busulfan

Busulfan is a potent chemotherapy medication primarily used in the treatment of certain cancers, particularly in preparation for stem cell transplantation. It belongs to a class of drugs known as alkylating agents, which work by interfering with the DNA of rapidly dividing cells.

Busulfan

Key Takeaways

  • Busulfan is an alkylating agent used in chemotherapy, especially for conditioning before stem cell transplants.
  • It works by damaging the DNA of cancer cells, preventing their growth and division.
  • Primary uses include treating chronic myeloid leukemia and other hematologic malignancies.
  • Common side effects include nausea, vomiting, hair loss, and fatigue, while serious risks involve myelosuppression and liver complications.
  • Patients should consult a comprehensive busulfan drug information patient guide for detailed safety and usage instructions.

What is Busulfan?

Busulfan is a cytotoxic chemotherapy drug classified as an alkylating agent. It functions by cross-linking DNA strands within cells, which prevents them from replicating and ultimately leads to cell death. This mechanism makes it particularly effective against rapidly dividing cells, such as cancer cells and those in the bone marrow.

Administered intravenously or orally, Busulfan is a critical component of various treatment regimens, especially in the context of preparing the body for a stem cell transplant. Its precise dosing and administration are crucial due to its narrow therapeutic index and potential for significant side effects.

Busulfan Uses and How It Works

Busulfan is primarily used as a conditioning regimen before hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplantation. This process aims to eliminate existing bone marrow cells, including cancerous ones, to make way for transplanted healthy stem cells. It is commonly employed in the treatment of various hematologic malignancies, such as chronic myeloid leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndromes, and certain lymphomas.

The core mechanism explaining how busulfan chemotherapy works involves its ability to alkylate DNA. This chemical modification creates cross-links and breaks in the DNA, disrupting its structure and function. As a result, cells, particularly those that are rapidly proliferating like cancer cells, are unable to repair their DNA, leading to programmed cell death (apoptosis). This cytotoxic effect is essential for eradicating malignant cells and immunosuppressing the patient to prevent rejection of the new stem cells. According to the World Health Organization (WHO), alkylating agents like Busulfan are fundamental in global cancer treatment strategies, especially for blood cancers.

Busulfan Side Effects and Warnings

Patients undergoing treatment with Busulfan may experience a range of busulfan side effects and warnings, which can vary in severity. Due to its potent nature, careful monitoring by healthcare professionals is essential throughout the treatment period. Common side effects often include:

  • Nausea and vomiting
  • Hair loss (alopecia)
  • Fatigue and weakness
  • Oral mucositis (inflammation and sores in the mouth)
  • Diarrhea

More serious side effects can also occur, such as severe myelosuppression (a decrease in blood cell production, leading to anemia, increased risk of infection, and bleeding), veno-occlusive disease of the liver (a potentially life-threatening liver complication), and seizures. Patients are advised to consult a comprehensive busulfan drug information patient guide provided by their healthcare team or pharmacist. This guide offers detailed information on potential adverse reactions, drug interactions, and important safety precautions, empowering patients to understand and manage their treatment effectively.

[EN] Cancer Types

Cancer Clinical Trial Options

Specialized matching specifically for oncology clinical trials and cancer care research.

Your Birthday


By filling out this form, you’re consenting only to release your medical records. You’re not agreeing to participate in clinical trials yet.